Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries

Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.

‘Against all odds’: The inside story of how scientists across three continents produced an Ebola vaccine

For years, researchers who studied Ebola had tried to develop vaccines and drugs to combat the virus. And for years, they had seen promising work stimied by no potential for drug makers to recoup development costs; and the sporardic nature of Ebola outbreaks provided little opportunity to subject experimental vaccines to rigorous tests.

Researchers to Develop Vaccines, Therapies for Nipah and Hendra Viruses

The Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million to advance treatments for the highly lethal henipaviruses, Nipah and Hendra.